Key Takeaways:
(P1) A class-action lawsuit was filed against Gossamer Bio, Inc. (NASDAQ: GOSS) after the company’s stock price collapsed by more than 80% following the failure of a key clinical trial. The lawsuit, announced by multiple shareholder rights law firms, alleges the company made false and misleading statements regarding its Phase 3 PROSERA study.
(P2) "Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the study design," according to a complaint filed in the case. The Schall Law Firm and Robbins LLP are among the firms reminding investors of the lawsuit.
(P3) The allegations center on the PROSERA study for seralutinib, a treatment for pulmonary arterial hypertension. On February 23, 2026, Gossamer announced the study failed to meet its primary endpoint. The company’s stock fell from $2.13 per share on February 20 to $0.42 in a single day. Gossamer attributed the failure to an unexpectedly high placebo response at its Latin American testing sites.
(P4) The lawsuit claims the company was not forthcoming about risks in the study's design, causing investors to purchase shares at artificially inflated prices. Investors who purchased stock during the class period of June 16, 2025, to February 20, 2026, now have until June 1, 2026, to file to be a lead plaintiff.
The core of the complaint is that Gossamer expressed confidence in the trial's design while allegedly knowing about, but not disclosing, issues with controlling for the placebo response. The study's primary endpoint was the change in six-minute walk distance (6MWD) at 24 weeks. The result of a +13.3 meter placebo-adjusted gain had a p-value of 0.0320, which narrowly missed the statistical significance threshold of 0.025.
The sharp stock decline wiped out significant shareholder value, putting the stock at its lowest levels. The outcome of this securities litigation will be the next major catalyst for the company, potentially involving significant financial damages and further impacting its ability to fund future research.
This article is for informational purposes only and does not constitute investment advice.
